Contineum Therapeutics Files Routine Board Option Grant (Form 4)

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. (CTNM) – Form 4 filing dated June 26, 2025

Non-employee director Olivia C. Ware received an automatic annual stock-option award under the company’s 2024 Equity Incentive Plan. The grant covers 14,750 options to purchase Class A common shares at an exercise price of $4.01 per share. The options vest in full on the earlier of (i) June 26, 2026 (one-year anniversary) or (ii) the next regular annual meeting of stockholders, contingent on continued board service, and expire on June 25, 2035. Following the grant, Ware beneficially owns 14,750 derivative securities, reported as direct ownership. No common shares were bought or sold, and no cash changed hands; the transaction is a routine component of the board’s compensation program and results in only de-minimis dilution to existing shareholders.

Positive

• Alignment of incentives: Options link director compensation to future share performance, potentially fostering shareholder-friendly decisions.

Negative

• Minor dilution: Issuance of 14,750 options incrementally increases the fully-diluted share count, albeit immaterial.

Insights

Financial Analyst

TL;DR: Routine director option grant; negligible dilution; neutral to valuation.

The Form 4 discloses a standard, pre-scheduled option award to director Olivia Ware. With just 14,750 underlying shares, the potential dilution is immaterial relative to CTNM’s outstanding share count (not disclosed here but presumed significantly larger). Exercise price of $4.01 anchors the option value close to the market at grant, aligning incentives without immediate cash outlay. No shares were sold, so insider sentiment cannot be inferred. Overall impact on earnings, cash flow, or strategic direction is negligible, rendering the filing informational rather than market-moving.

Corporate Governance Expert

TL;DR: Filing confirms compliance with board compensation policy; governance-neutral.

The grant follows CTNM’s Non-Employee Director Compensation Program, illustrating procedural adherence and transparent disclosure under Section 16(a). One-year cliff vesting encourages board continuity while maintaining alignment with shareholder interests. There are no red-flags—no accelerated vesting, below-market pricing, or unusual volumes. From a governance standpoint, this is a predictable, policy-driven action with no material ramifications for investors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ware Olivia C

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.01	06/26/2025		A		14,750		(1)	06/25/2035	Class A Common Stock	14,750	$0	14,750	D

Explanation of Responses:

1. Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

	/s/ Peter Slover, Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CTNM file on June 26, 2025?

Contineum Therapeutics filed a Form 4 reporting a stock-option grant to director Olivia C. Ware.

How many CTNM options were granted to Olivia Ware?

She received 14,750 stock options for Class A common shares.

What is the exercise price of the newly issued options?

The exercise price is $4.01 per share.

When will the options vest?

They vest on the earlier of June 26, 2026 or the next annual stockholder meeting, assuming continuous service.

Does the filing involve a purchase or sale of CTNM common shares?

No. It reports an option grant; no common shares were bought or sold.

What is the expiration date of the options?

The options expire on June 25, 2035.

Is this transaction expected to materially affect CTNM’s share count?

Impact is immaterial; 14,750 shares represent a negligible fraction of total shares outstanding.